FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952314558> ?p ?o ?g. }

• W2952314558 endingPage "1664" @default.
• W2952314558 startingPage "1653" @default.
• W2952314558 abstract "Accounting for more than 70% of ovarian cancer cases, epithelial ovarian malignancy has a low 5-year survival rate. MicroRNAs may be targeted in the clinical treatment of the disease. In this study, we first found that miR-1251-5p was significantly upregulated in human ovarian cancer cell lines and tissues with the cancer progression and stages. Overexpression or inhibition of miR-1251-5p promoted or impeded cell proliferation and cell cycle progression. Subsequently, TBCC, one of the tubulin-binding cofactors (TBCs), was identified as a target of miR-1251-5p to be negatively associated with cell cycle and autophagy. Exogenous overexpression of TBCC inhibited the expressions of CDK4 and LC3BII, but it promoted the expressions of α/β-tubulin and p62 to suppress cell growth and autophagy, particularly under the starving condition; whereas the introduction of miR-1251-5p in TBCC-overexpressing cells rescued the suppressive effects of TBCC on cell cycle and autophagy through the inverse regulation of the above proteins. Finally, miR-1251-5p was proven to enhance xenograft tumor growth through the downregulation of TBCC but upregulation of Ki67 and LC3B in xenograft tumor tissues. Collectively, these results suggest that miR-1251-5p functions as an oncogene to suppress TBCC and α/β-tubulin expression. Thus, the miR-1251-5p/TBCC/α/β-tubulin axis may be targeted for ovarian cancer treatment. Accounting for more than 70% of ovarian cancer cases, epithelial ovarian malignancy has a low 5-year survival rate. MicroRNAs may be targeted in the clinical treatment of the disease. In this study, we first found that miR-1251-5p was significantly upregulated in human ovarian cancer cell lines and tissues with the cancer progression and stages. Overexpression or inhibition of miR-1251-5p promoted or impeded cell proliferation and cell cycle progression. Subsequently, TBCC, one of the tubulin-binding cofactors (TBCs), was identified as a target of miR-1251-5p to be negatively associated with cell cycle and autophagy. Exogenous overexpression of TBCC inhibited the expressions of CDK4 and LC3BII, but it promoted the expressions of α/β-tubulin and p62 to suppress cell growth and autophagy, particularly under the starving condition; whereas the introduction of miR-1251-5p in TBCC-overexpressing cells rescued the suppressive effects of TBCC on cell cycle and autophagy through the inverse regulation of the above proteins. Finally, miR-1251-5p was proven to enhance xenograft tumor growth through the downregulation of TBCC but upregulation of Ki67 and LC3B in xenograft tumor tissues. Collectively, these results suggest that miR-1251-5p functions as an oncogene to suppress TBCC and α/β-tubulin expression. Thus, the miR-1251-5p/TBCC/α/β-tubulin axis may be targeted for ovarian cancer treatment." @default.
• W2952314558 created "2019-06-27" @default.
• W2952314558 creator A5001563192 @default.
• W2952314558 creator A5002607371 @default.
• W2952314558 creator A5031499083 @default.
• W2952314558 creator A5047936883 @default.
• W2952314558 creator A5080609124 @default.
• W2952314558 creator A5088684298 @default.
• W2952314558 date "2019-09-01" @default.
• W2952314558 modified "2023-10-18" @default.
• W2952314558 title "MicroRNA-1251-5p Promotes Carcinogenesis and Autophagy via Targeting the Tumor Suppressor TBCC in Ovarian Cancer Cells" @default.
• W2952314558 cites W130200399 @default.
• W2952314558 cites W1495956204 @default.
• W2952314558 cites W1551376656 @default.
• W2952314558 cites W1980063107 @default.
• W2952314558 cites W1996234606 @default.
• W2952314558 cites W2041517220 @default.
• W2952314558 cites W2047578735 @default.
• W2952314558 cites W2127316729 @default.
• W2952314558 cites W2155725868 @default.
• W2952314558 cites W2346650944 @default.
• W2952314558 cites W2492412617 @default.
• W2952314558 cites W2533981955 @default.
• W2952314558 cites W2549890734 @default.
• W2952314558 cites W2554230517 @default.
• W2952314558 cites W2576628557 @default.
• W2952314558 cites W2614890681 @default.
• W2952314558 cites W2615970406 @default.
• W2952314558 cites W2731860601 @default.
• W2952314558 cites W2781525129 @default.
• W2952314558 cites W2785021707 @default.
• W2952314558 cites W2809487874 @default.
• W2952314558 cites W2898966876 @default.
• W2952314558 cites W2898996259 @default.
• W2952314558 cites W2899058344 @default.
• W2952314558 cites W2899281695 @default.
• W2952314558 cites W2900332767 @default.
• W2952314558 cites W2900483681 @default.
• W2952314558 cites W2901014197 @default.
• W2952314558 cites W2902062814 @default.
• W2952314558 cites W2903230904 @default.
• W2952314558 cites W2904288110 @default.
• W2952314558 cites W2904422990 @default.
• W2952314558 cites W2905275906 @default.
• W2952314558 cites W2906427523 @default.
• W2952314558 cites W2911637230 @default.
• W2952314558 cites W2990967807 @default.
• W2952314558 doi "https://doi.org/10.1016/j.ymthe.2019.06.005" @default.
• W2952314558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6731176" @default.
• W2952314558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31278033" @default.
• W2952314558 hasPublicationYear "2019" @default.
• W2952314558 type Work @default.
• W2952314558 sameAs 2952314558 @default.
• W2952314558 citedByCount "26" @default.
• W2952314558 countsByYear W29523145582019 @default.
• W2952314558 countsByYear W29523145582020 @default.
• W2952314558 countsByYear W29523145582021 @default.
• W2952314558 countsByYear W29523145582022 @default.
• W2952314558 countsByYear W29523145582023 @default.
• W2952314558 crossrefType "journal-article" @default.
• W2952314558 hasAuthorship W2952314558A5001563192 @default.
• W2952314558 hasAuthorship W2952314558A5002607371 @default.
• W2952314558 hasAuthorship W2952314558A5031499083 @default.
• W2952314558 hasAuthorship W2952314558A5047936883 @default.
• W2952314558 hasAuthorship W2952314558A5080609124 @default.
• W2952314558 hasAuthorship W2952314558A5088684298 @default.
• W2952314558 hasBestOaLocation W29523145581 @default.
• W2952314558 hasConcept C104317684 @default.
• W2952314558 hasConcept C121608353 @default.
• W2952314558 hasConcept C127561419 @default.
• W2952314558 hasConcept C145059251 @default.
• W2952314558 hasConcept C190283241 @default.
• W2952314558 hasConcept C203522944 @default.
• W2952314558 hasConcept C2780427987 @default.
• W2952314558 hasConcept C2781018059 @default.
• W2952314558 hasConcept C29537977 @default.
• W2952314558 hasConcept C502942594 @default.
• W2952314558 hasConcept C54355233 @default.
• W2952314558 hasConcept C555283112 @default.
• W2952314558 hasConcept C62112901 @default.
• W2952314558 hasConcept C67082663 @default.
• W2952314558 hasConcept C86803240 @default.
• W2952314558 hasConceptScore W2952314558C104317684 @default.
• W2952314558 hasConceptScore W2952314558C121608353 @default.
• W2952314558 hasConceptScore W2952314558C127561419 @default.
• W2952314558 hasConceptScore W2952314558C145059251 @default.
• W2952314558 hasConceptScore W2952314558C190283241 @default.
• W2952314558 hasConceptScore W2952314558C203522944 @default.
• W2952314558 hasConceptScore W2952314558C2780427987 @default.
• W2952314558 hasConceptScore W2952314558C2781018059 @default.
• W2952314558 hasConceptScore W2952314558C29537977 @default.
• W2952314558 hasConceptScore W2952314558C502942594 @default.
• W2952314558 hasConceptScore W2952314558C54355233 @default.
• W2952314558 hasConceptScore W2952314558C555283112 @default.
• W2952314558 hasConceptScore W2952314558C62112901 @default.
• W2952314558 hasConceptScore W2952314558C67082663 @default.
• W2952314558 hasConceptScore W2952314558C86803240 @default.
• W2952314558 hasFunder F4320321001 @default.

• next